Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BEPREVE vs ALAWAY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bepotastine besilate is a selective histamine H1 receptor antagonist. It inhibits histamine-induced vascular permeability, pruritus, and conjunctival inflammation.
ALAWAY (cetirizine ophthalmic solution) is a selective histamine H1-receptor antagonist that inhibits histamine release from mast cells, reducing ocular itching and allergic conjunctivitis symptoms.
FDA: Treatment of ocular itching associated with allergic conjunctivitis
Treatment of ocular itching associated with allergic conjunctivitis
1 drop in the affected eye(s) twice daily (approximately every 6-8 hours).
2 doses (each dose = 2 sprays) per nostril, repeated every 12 hours as needed. Each spray delivers 50 mg of sodium cromoglicate. Route: intranasal. Maximum: 2 doses per nostril per day.
Plasma elimination half-life is approximately 2-3 hours in healthy adults. In patients with renal impairment, half-life may be prolonged (up to 6-8 hours in severe impairment).
Terminal elimination half-life of 3-4 hours in healthy adults; extended to 10-15 hours in severe renal impairment (Cr Cl <30 m L/min). Clinical context: Twice-daily dosing is standard; dose adjustment required in renal insufficiency.
Minimally metabolized; 80% excreted unchanged in urine.
Not extensively metabolized in the eye; systemic metabolism by hepatic CYP450 enzymes is minimal due to low systemic absorption.
Bepotastine besilate is primarily excreted via renal elimination. Approximately 75-80% of the administered dose is eliminated unchanged in the urine, with less than 10% recovered in feces. Minor biliary excretion occurs.
Primarily renal excretion (80-90% unchanged drug) via glomerular filtration and active tubular secretion; 10-20% fecal excretion. Minimal biliary elimination.
Approximately 55% bound to plasma proteins, primarily albumin.
Approximately 65-75% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Volume of distribution is approximately 0.8 L/kg, indicating distribution into total body water. This suggests moderate tissue penetration.
Vd: 1.0-1.5 L/kg, indicating extensive distribution into total body water and tissues; high penetration into ocular tissues and respiratory mucosa.
Ophthalmic: Systemic bioavailability is low (less than 1%) due to local administration and limited absorption. No oral bioavailability data as the drug is not administered systemically.
Oral: ~50% due to first-pass metabolism (CYP3A4 and P-glycoprotein). Ophthalmic solution: negligible systemic absorption (<0.5% of topical dose). Intravenous: 100%.
No dose adjustment required for renal impairment.
No dosage adjustment required. Sodium cromoglicate is primarily excreted unchanged in urine, but no specific GFR-based adjustments are recommended due to wide safety margin.
No dose adjustment required for hepatic impairment.
No dosage adjustment required. Sodium cromoglicate is minimally metabolized and undergoes biliary excretion; however, no specific Child-Pugh based modifications are established.
Safety and efficacy in pediatric patients below 2 years of age have not been established. For pediatric patients 2 years and older, same as adult dose: 1 drop twice daily.
Children 2-5 years: 1 spray per nostril every 6-8 hours as needed. Children 6 years and older: same as adult (2 sprays per nostril every 12 hours). Maximum 2 doses per nostril per day in all age groups. Weight-based dosing not established.
No specific dose adjustment required; dosing same as for younger adults.
No specific dose adjustment required; use same adult dose. Caution in elderly with renal impairment due to potential accumulation, though clinical significance is minimal.
None
None
Not for injection; for topical ophthalmic use only.,Avoid wearing contact lenses if eyes are red.,May cause transient stinging or burning upon instillation.
For topical ophthalmic use only,Do not inject,Contact lens wearers should remove lenses before instillation and wait at least 10 minutes before reinserting,May cause temporary blurred vision,Avoid touching dropper tip to any surface to prevent contamination
Hypersensitivity to bepotastine or any component of the formulation.
Hypersensitivity to cetirizine or any component of the formulation
No known food interactions.
No specific food interactions with Alaway ophthalmic solution. Take as directed, regardless of meals. Avoid rubbing eyes after application.
No adequate and well-controlled studies in pregnant women. Animal studies revealed no evidence of teratogenicity or fetotoxicity at doses up to 2000 times the human ocular dose. Risk cannot be ruled out; use only if potential benefit justifies potential risk to the fetus.
ALAWAY (azelastine) is classified as FDA Pregnancy Category C. In animal studies, azelastine administered orally during organogenesis produced fetal malformations (cleft palate, skeletal abnormalities) at maternally toxic doses (≥ 30 mg/kg/day in rats, 68 times the maximum recommended human intranasal dose). There are no adequate and well-controlled studies in pregnant women. First trimester: Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. Second and third trimesters: Limited data; avoid use unless necessary due to lack of safety evidence.
Excretion in human milk unknown; caution advised. M/P ratio not available. Consider developmental and health benefits of breastfeeding along with mother's clinical need.
Azelastine is excreted in human breast milk; the milk-to-plasma ratio (M/P) is unknown. In a study of intranasal azelastine (2 sprays per nostril twice daily), the estimated daily infant dose via breast milk is 0.7% of the maternal dose, which is considered low. However, due to the potential for adverse effects in nursing infants (e.g., somnolence, irritability), caution is advised. Use only if clearly needed and benefit outweighs risk. Consider alternative therapies with more safety data.
No pharmacokinetic data in pregnancy; no dosage adjustment recommended. Use standard adult dosing.
No specific dose adjustments are recommended for pregnancy. However, pharmacokinetic changes during pregnancy (e.g., increased plasma volume, altered hepatic metabolism) may reduce azelastine systemic exposure; the clinical significance is unknown. Use the lowest effective dose for the shortest duration. Maximum recommended intranasal dose: 2 sprays per nostril twice daily (total 548 mcg/day). Avoid exceeding this dose.
Bepotastine besilate (Bepreve) is a topical antihistamine and mast cell stabilizer for ocular allergy. Onset of action is within 3 minutes, duration up to 8 hours. May cause transient stinging. Do not use while wearing contact lenses; insert lenses 10 minutes after instillation.
Alaway (ketotifen fumarate ophthalmic solution) is used for prevention of itching associated with allergic conjunctivitis. It is a mast cell stabilizer with antihistamine properties. Onset of action occurs within minutes, but may require several days of use for full effect. Advise patients to avoid wearing contact lenses if eyes are red. Remove contacts before instillation and wait at least 10 minutes before reinserting.
Instill one drop into the affected eye(s) twice daily.,Remove contact lenses before use; wait at least 10 minutes before reinserting.,Do not touch the dropper tip to any surface to avoid contamination.,May cause temporary blurred vision; avoid driving until vision clears.,Report any signs of infection or worsening symptoms to your doctor.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before using this medication; wait at least 10 minutes after using drops before reinserting.,Use as directed, typically one drop in each affected eye twice daily, with at least 6-8 hours between doses.,Do not use while wearing contact lenses if eyes are red or irritated.,Temporary burning or stinging may occur upon instillation.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BEPREVE vs ALAWAY, answered by our medical review team.
BEPREVE is a Ophthalmic Antihistamine that works by Bepotastine besilate is a selective histamine H1 receptor antagonist. It inhibits histamine-induced vascular permeability, pruritus, and conjunctival inflammation.. ALAWAY is a Ophthalmic Antihistamine that works by ALAWAY (cetirizine ophthalmic solution) is a selective histamine H1-receptor antagonist that inhibits histamine release from mast cells, reducing ocular itching and allergic conjunctivitis symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BEPREVE and ALAWAY depend on the specific clinical indication. These are both Ophthalmic Antihistamine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BEPREVE is: 1 drop in the affected eye(s) twice daily (approximately every 6-8 hours).. The standard adult dose of ALAWAY is: 2 doses (each dose = 2 sprays) per nostril, repeated every 12 hours as needed. Each spray delivers 50 mg of sodium cromoglicate. Route: intranasal. Maximum: 2 doses per nostril per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BEPREVE and ALAWAY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BEPREVE is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies revealed no evidence of teratogenicity or fetotoxicity at doses up to 2000 times the human ocular dose. Ri. ALAWAY is classified as Category C. ALAWAY (azelastine) is classified as FDA Pregnancy Category C. In animal studies, azelastine administered orally during organogenesis produced fetal malformations (cleft palate, sk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.